Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

278 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Efficacy, safety and tolerability of linezolid containing regimens in treating MDR-TB and XDR-TB: systematic review and meta-analysis.
Sotgiu G, Centis R, D'Ambrosio L, Alffenaar JW, Anger HA, Caminero JA, Castiglia P, De Lorenzo S, Ferrara G, Koh WJ, Schecter GF, Shim TS, Singla R, Skrahina A, Spanevello A, Udwadia ZF, Villar M, Zampogna E, Zellweger JP, Zumla A, Migliori GB. Sotgiu G, et al. Among authors: spanevello a. Eur Respir J. 2012 Dec;40(6):1430-42. doi: 10.1183/09031936.00022912. Epub 2012 Apr 10. Eur Respir J. 2012. PMID: 22496332 Free article. Review.
Extensively drug-resistant tuberculosis is worse than multidrug-resistant tuberculosis: different methodology and settings, same results.
Migliori GB, Lange C, Girardi E, Centis R, Besozzi G, Kliiman K, Ortmann J, Matteelli A, Spanevello A, Cirillo DM; SMIRA/TBNET Study Group. Migliori GB, et al. Among authors: spanevello a. Clin Infect Dis. 2008 Mar 15;46(6):958-9. doi: 10.1086/528875. Clin Infect Dis. 2008. PMID: 18288911 Free article. No abstract available.
Consensus not yet reached on key drugs for extensively drug-resistant tuberculosis treatment.
Migliori GB, Sotgiu G, D'Arcy Richardson M, Centis R, Guenther G, Hoffmann H, Cirillo DM, Toungossova O, Kliiman K, De Lorenzo S, Spanevello A, Lange C; Tuberculosis Network European Trialsgroup. Migliori GB, et al. Among authors: spanevello a. Clin Infect Dis. 2009 Jul 15;49(2):315-6; author reply 317. doi: 10.1086/600060. Clin Infect Dis. 2009. PMID: 19538069 No abstract available.
Comment on: Daily 300 mg dose of linezolid for the treatment of intractable multidrug-resistant and extensively drug-resistant tuberculosis.
Sotgiu G, Lange C, Richardson MD, Matteelli A, Centis R, Eker B, Guenther G, Spanevello A, Migliori GB; TBNET. Sotgiu G, et al. Among authors: spanevello a. J Antimicrob Chemother. 2009 Oct;64(4):879-83; author reply 883-4. doi: 10.1093/jac/dkp265. Epub 2009 Aug 3. J Antimicrob Chemother. 2009. PMID: 19651787 No abstract available.
Outcomes of patients with drug-resistant-tuberculosis treated with bedaquiline-containing regimens and undergoing adjunctive surgery.
Borisov SE, D'Ambrosio L, Centis R, Tiberi S, Dheda K, Alffenaar JW, Amale R, Belilowski E, Bruchfeld J, Canneto B, Denholm J, Duarte R, Esmail A, Filippov A, Davies Forsman L, Gaga M, Ganatra S, Igorevna GA, Lazaro Mastrapa B, Manfrin V, Manga S, Maryandyshev A, Massard G, González Montaner P, Mullerpattan J, Palmero DJ, Pontarelli A, Papavasileiou A, Pontali E, Romero Leyet R, Spanevello A, Udwadia ZF, Viggiani P, Visca D, Sotgiu G, Migliori GB. Borisov SE, et al. Among authors: spanevello a. J Infect. 2019 Jan;78(1):35-39. doi: 10.1016/j.jinf.2018.08.003. Epub 2018 Aug 7. J Infect. 2019. PMID: 30096332
Pulmonary rehabilitation is effective in patients with tuberculosis pulmonary sequelae.
Visca D, Zampogna E, Sotgiu G, Centis R, Saderi L, D'Ambrosio L, Pegoraro V, Pignatti P, Muňoz-Torrico M, Migliori GB, Spanevello A. Visca D, et al. Among authors: spanevello a. Eur Respir J. 2019 Mar 14;53(3):1802184. doi: 10.1183/13993003.02184-2018. Print 2019 Mar. Eur Respir J. 2019. PMID: 30872556 Free article. No abstract available.
Surveillance of adverse events in the treatment of drug-resistant tuberculosis: A global feasibility study.
Akkerman O, Aleksa A, Alffenaar JW, Al-Marzouqi NH, Arias-Guillén M, Belilovski E, Bernal E, Boeree MJ, Borisov SE, Bruchfeld J, Cadiñanos Loidi J, Cai Q, Caminero JA, Cebrian Gallardo JJ, Centis R, Codecasa LR, D'Ambrosio L, Dalcolmo M, Danila E, Dara M, Davidavičienė E, Davies Forsman L, De Los Rios Jefe J, Denholm J, Duarte R, Elamin SE, Ferrarese M, Filippov A, Ganatra S, Garcia A, García-García JM, Gayoso R, Giraldo Montoya AM, Gomez Rosso RG, Gualano G, Hoefsloot W, Ilievska-Poposka B, Jonsson J, Khimova E, Kuksa L, Kunst H, Laniado-Laborín R, Li Y, Magis-Escurra C, Manfrin V, Manga S, Marchese V, Martínez Robles E, Maryandyshev A, Matteelli A, Migliori GB, Mullerpattan JB, Munoz-Torrico M, Mustafa Hamdan H, Nieto Marcos M, Noordin NM, Palmero DJ, Palmieri F, Payen MC, Piubello A, Pontali E, Pontarelli A, Quirós S, Rendon A, Skrahina A, Šmite A, Solovic I, Sotgiu G, Souleymane MB, Spanevello A, Stošić M, Tadolini M, Tiberi S, Udwadia ZF, van den Boom M, Vescovo M, Viggiani P, Visca D, Zhurkin D, Zignol M; members of the International Study Group on new anti-tuberculosis drugs and adverse events monitoring. Akkerman O, et al. Among authors: spanevello a. Int J Infect Dis. 2019 Jun;83:72-76. doi: 10.1016/j.ijid.2019.03.036. Epub 2019 Apr 3. Int J Infect Dis. 2019. PMID: 30953827 Free article.
278 results